Home LiteratureArticle Details
PMID: 17102939 Published · ppublish English Comparative Study Journal Article

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Naunyn-Schmiedeberg's archives of pharmacology ·Vol. 374 ·No. 3 ·2006-12-00 ·Pages 195-206

Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M

Abstract

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline (MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin (PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine- or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase (eNOS) expression. MC-rat lungs showed a significant decrease of eNOS (P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension (RVP in mmHg: 30 +/- 3, 36 +/- 4 vs. 45 +/- 4 and 14 +/- 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 +/- 0.04, 0.39 +/- 0.03, 0.62 +/- 0.05 and 0.29 +/- 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05),and reduced MC-induced thickening (61 +/- 6 microm, 82 +/- 5 microm, 154 +/- 4 microm, and 59 +/- 2 microm for MC + PS, MC + AS, MC, and control groups, respectively; P = 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (E(max)=65 +/- 5%, 49 +/- 6%, 46 +/- 3%, and 76 +/- 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.

MeSH Terms
Acetylcholine Animals Apoptosis/drug effects Atorvastatin Caspase 3/metabolism Endothelial Cells/drug effects,metabolism Heptanoic Acids/pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology Hypertension, Pulmonary/chemically induced,drug therapy Lung/drug effects,physiopathology Male Monocrotaline Nitric Oxide Synthase Type III/drug effects,metabolism Nitroprusside Pravastatin/pharmacology Pulmonary Artery/drug effects,physiopathology Pyrroles/pharmacology Rats Rats, Wistar Ventricular Pressure/drug effects
Chemicals
Heptanoic Acids Hydroxymethylglutaryl-CoA Reductase Inhibitors Pyrroles Nitroprusside Monocrotaline Atorvastatin Nitric Oxide Synthase Type III Caspase 3 Pravastatin Acetylcholine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Rakotoniaina Zo
Laboratory of Experimental Cardiovascular Physiopathology and Pharmacology (EA2979), University of Burgundy, BP 87900, 21000, Dijon, France.
Guerard Pascal
Lirussi Frederic
Goirand Françoise
Rochette Luc
Dumas Monique
Bardou Marc
References (52)
52 references, click to expand
  1. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
    Eur Heart J. 2006 Mar;27(5):589-95 PMID: 16431875
  2. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.
    Clin Pharmacokinet. 2000 Dec;39(6):397-412 PMID: 11192473
  3. Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition.
    J Cardiovasc Pharmacol. 2001 Aug;38(2):325-34 PMID: 11483882
  4. Pulmonary arterial hypertension: new insights and new hope.
    Respirology. 2006 Jan;11(1):6-17 PMID: 16423196
  5. Potential vascular benefits of statins.
    Am J Med. 2005 Dec;118 Suppl 12A:62-7 PMID: 16356810
  6. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
    J Clin Invest. 2001 Nov;108(10):1429-37 PMID: 11714734
  7. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    J Am Coll Cardiol. 2006 May 16;47(10 ):2049-56 PMID: 16697324
  8. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.
    Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L668-76 PMID: 16698853
  9. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
    Pharmacol Res. 1997 Aug;36(2):115-21 PMID: 9344639
  10. The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.
    J Atheroscler Thromb. 2005;12(6):338-42 PMID: 16394618
  11. Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload.
    Biochim Biophys Acta. 2002 Apr 24;1586(3):233-42 PMID: 11997075
  12. The activation pattern of the antioxidant enzymes in the right ventricle of rat in response to pressure overload is of heart failure type.
    Heart Dis. 2003 Sep-Oct;5(5):308-12 PMID: 14503927
  13. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
    Cardiovasc Res. 2000 Sep;47(4):648-57 PMID: 10974215
  14. Effects of nicorandil on monocrotaline-induced pulmonary arterial hypertension in rats.
    J Cardiovasc Pharmacol. 2005 Oct;46(4):452-8 PMID: 16160596
  15. How valid are animal models to evaluate treatments for pulmonary hypertension?
    Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):391-400 PMID: 16932922
  16. [Pulmonary artery hypertension associated with connective tissue diseases].
    Presse Med. 2003 May 17;32(17):789-99 PMID: 12856325
  17. Direct vascular effects of HMG-CoA reductase inhibitors.
    Trends Cardiovasc Med. 2000 May;10(4):143-8 PMID: 11239793
  18. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.
    Nat Rev Drug Discov. 2005 Dec;4(12):977-87 PMID: 16341063
  19. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Am Heart J. 2006 Apr;151(4):851.e1-5 PMID: 16569546
  20. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase.
    Eur J Vasc Endovasc Surg. 2001 Apr;21(4):295-300 PMID: 11359328
  21. Simvastatin treatment of pulmonary hypertension: an observational case series.
    Chest. 2005 Apr;127(4):1446-52 PMID: 15821229
  22. Statin mediated protection of the ischemic myocardium.
    Vascul Pharmacol. 2005 Apr-May;42(5-6):265-70 PMID: 15922259
  23. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
    Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14 PMID: 16896805
  24. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
    Mol Pharmacol. 2001 Mar;59(3):646-54 PMID: 11179461
  25. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation.
    Circ Res. 1996 Dec;79(6):1131-42 PMID: 8943951
  26. [Collagen diseases with pulmonary hypertension].
    Nihon Rinsho Meneki Gakkai Kaishi. 2004 Jun;27(3):127-36 PMID: 15291249
  27. Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
    Naunyn Schmiedebergs Arch Pharmacol. 2006 Jun;373(3):221-9 PMID: 16736159
  28. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
    Arthritis Rheum. 2006 Jan;54(1):184-91 PMID: 16385514
  29. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Curr Med Res Opin. 2005 Sep;21(9):1389-99 PMID: 16197657
  30. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
    Circulation. 1998 Mar 31;97(12):1129-35 PMID: 9537338
  31. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
    Intern Med. 2006;45(2):51-5 PMID: 16484739
  32. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
    Circulation. 2001 Aug 21;104(8):945-50 PMID: 11514384
  33. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.
    Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8 PMID: 12406854
  34. Primary and secondary pulmonary hypertension in systemic lupus erythematosus.
    Lupus. 2000;9(5):338-42 PMID: 10878725
  35. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.
    Circulation. 2003 Sep 30;108(13):1640-5 PMID: 12963647
  36. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells.
    Toxicol Appl Pharmacol. 1998 Aug;151(2):236-44 PMID: 9707500
  37. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
    Atherosclerosis. 2000 Sep;152(1):217-27 PMID: 10996358
  38. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
    Am J Cardiol. 2005 Sep 5;96(5A):11F-23F PMID: 16126019
  39. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin.
    Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H938-45 PMID: 12750068
  40. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost.
    Rheumatol Int. 2006 Jan;26(3):264-9 PMID: 16010558
  41. Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow.
    Heart Vessels. 2006 May;21(3):169-79 PMID: 16715192
  42. Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation.
    Biochem Biophys Res Commun. 1999 Sep 16;263(1):118-22 PMID: 10486263
  43. Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
    Atherosclerosis. 2003 Jul;169(1):19-29 PMID: 12860247
  44. Statin-stimulated nitric oxide release from endothelium.
    Med Sci Monit. 2001 Jul-Aug;7(4):622-7 PMID: 11433186
  45. Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.
    Am J Cardiol. 2006 Apr 1;97(7):1002-6 PMID: 16563905
  46. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells.
    Atherosclerosis. 2003 Oct;170(2):237-43 PMID: 14612203
  47. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Am Heart J. 2006 Feb;151(2):273-81 PMID: 16442888
  48. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Eur J Clin Invest. 2005 Aug;35(8):476-81 PMID: 16101667
  49. Statins as anti-inflammatory agents.
    Trends Pharmacol Sci. 2002 Oct;23(10):482-6 PMID: 12368073
  50. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Am J Cardiovasc Drugs. 2001;1(6):411-20 PMID: 14728000
  51. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
    Biochem Pharmacol. 2004 Jun 15;67(12):2175-86 PMID: 15163549
  52. A factor preventing the major head protein of bacteriophage T4 from random aggregation.
    J Mol Biol. 1970 Jan 14;47(1):69-85 PMID: 5413343
Article Info
Journal
Naunyn-Schmiedeberg's archives of pharmacology
Abbr.
Naunyn Schmiedebergs Arch Pharmacol
ISSN
0028-1298
Published
2006-12-00
Epub
2006-00-11
Pages
195-206
Language
English
Region
Germany
NLM ID
0326264
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]